Amgen
In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026. Regulatory filings and recent market data indicate a coordinated accumulation by major asset managers, who are increasingly viewing the California-based biotech giant
Eli Lilly
As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the healthcare sector has emerged as the market's primary engine of growth. The Dow Jones Industrial
Amgen
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant announcement, made well in advance of the payment date, underscores the company's robust financial health and unwavering
Amgen
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to reach $296.93 USD. This significant uptick is attributed to a powerful combination of strategic manufacturing investments, a pivotal